← Prestige Consumer Healthcare Inc. (PBH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Prestige Consumer Healthcare Inc. (PBH)
Pharmaceutical Preparations · market cap $2.2B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Prestige Consumer Healthcare Inc. (PBH) is a Tarrytown, NY-based OTC healthcare and household cleaning products company with $2.2B market cap and ~$1.1B in annual revenue. Despite its consumer-staples profile, the company carries an unexpected clinical-stage pipeline including two Phase 3 assets (HD204 in Lung Cancer, HD201 in HER2+ Breast Cancer) and a Phase 2 asset (PBP1510 in Pancreatic Cancer), creating a structural anomaly between its branded OTC core business and biopharma-style pipeline catalysts. The next scheduled catalyst is an August 6, 2026 earnings report.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| HD204 | Phase 3 | Lung Cancer |
| PBP1510 (400mg/16mL) | Phase 2 | Pancreatic Cancer |
| HD201 | Phase 3 | HER2 Positive Breast Cancer |
Price & technical context
3-month
-9.4%
6-month
-22.4%
12-month
-28.3%
52-wk range
$44.77–$70.21
vs 50-day MA
-10.4%
vs 200-day MA
-19.5%
Realized vol
32.7%
Max drawdown
-49.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PBH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.